Skip to content
DraconiticResearch
Search Sources API
210,423 studies31 sourcesUpdated 35 min ago

Oncology

5,311 studies490 in 7 days2,547 in 30 days

Filters
Type
Date
Clear

Latest

5,311 studies

  1. Disentangling policy and generational drivers of breast cancer screening in Türkiye
    S Keskin, AN Emecen
    The European Journal of Public HealthPeer-reviewedCC BY-NC 4.0Full textOncologyPMCEurope PMC
  2. Engineering clinically actionable nanomedicine for cancer immunometabolic ecosystem reprogramming
    Yuhong Gao, Xiulin Dong, Sijia Hua +3
    EBioMedicinePeer-reviewedCC BY-NCFull textOncologyEurope PMCCrossref
  3. Organ Preservation and Quality of Life After Total Neoadjuvant Treatment in Rectal Cancer
    Markus Diefenhardt, Emmanouil Fokas, Rebekka Kosmala +17
    JAMA network openPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCCrossref
  4. Safety Profiles of Immune Checkpoint Inhibitor Strategies in Gastrointestinal Cancers and Their Association With Clinical Outcomes: A Systematic Review and Meta‐Analysis
    Jing Lei, Yiyi Yu, Qing Liu +5
    Cancer medicinePeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCDOAJ
  5. European Cancer Information System: its role on Pancreatic Cancer surveillance
    L Barrachina-Bonet, G Bargues-Navarro, E González-Cantó +3
    The European Journal of Public HealthPeer-reviewedCC BY-NC 4.0Full textOncologyPMCEurope PMC
  6. Delays in seeking medical care for potential cancer symptoms
    A Yanes-Roldán, C Fernández-Iñigo, ML García-Vaquero +1
    The European Journal of Public HealthPeer-reviewedCC BY-NC 4.0Full textOncologyPMCEurope PMC
  7. N.5. Round Table: From Fragmentation to Integration in Cancer Prevention
    Sciensano (Belgium), UNICANCER (France), Léon Bérard Center (France), Gabrielle Schittecatte
    The European Journal of Public HealthPeer-reviewedCC BY-NC 4.0Full textOncologyPMCEurope PMC
  8. LncRNA AP003469.2 promotes hepatocellular carcinoma progression by regulating cuproptosis via the miR-4732-3p/LIPT1 axis
    Jinlong Huo, Shuman Kuang, Lin Wu +1
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  9. Polysaccharide-mediated modulation of gut microbiota and lysine lactylation: implications for tumor microenvironment remodeling and cancer immunotherapy
    Siwei Yang, Dongmei Long, Weixuan Qiu +7
    Frontiers in immunologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  10. Resection rates after conversion therapy for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis
    Xiaobo Ouyang, Ji Li, Po Liang +4
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  11. Continuous spatially informed microenvironment programs show cross-cohort concordance and context-dependent spatial organization in diffuse large B-cell lymphoma
    Junwei Yang, Han Li, Liuxin Jiang +6
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  12. The IFN-γ response cycle: decoupling tumor killing from evolutionary selection in cancer immunotherapy
    Baiyu Wang, Delong Zhao, Yuehan Ma +1
    Frontiers in immunologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  13. Survival and prognostic factors analysis of carbon ion radiotherapy for limited-stage small cell lung cancer
    Xuexue Liang, Qinli Gong, Yihe Zhang +7
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  14. Anti‐PD‐1/CTLA‐4 bispecific antibody‐based combination therapy for cervical cancer: a multicenter study with biomarker analysis
    Jiwei Li, Yuping Deng, Tao Wu +4
    Frontiers in immunologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  15. Inflammatory breast cancer among advanced breast malignancies: diagnostic, microenvironmental, and therapeutic challenges of the rare amongst the common
    Shayla Murray, Matthew Becker, Bora Lim
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  16. Single-cell profiling of peripheral immune remodeling in BK polyomavirus–associated nephropathy after kidney transplantation
    Hyunjoo Bae, Eun Jeong Ko, Byung Ha Chung +1
    Frontiers in immunologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  17. Case Report: Severe multi-organ damage induced by cadonilimab: mechanism investigation and management strategies
    Bin Shan, Ruixia Yang, Yi Peng +1
    Frontiers in immunologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  18. Molecular profiling and prognostic significance of gastric cancer subtypes based on extracellular vesicle-related characteristics
    Guangyu Ding, Chenjie Xu, Xingmao Huang +12
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  19. CGRP remodels the acidic microenvironment and promotes pancreatic carcinoma progression by regulating NHE1 and CA9
    Sa Liu, Shanshan Wei, Taoli Sun +5
    Frontiers in pharmacologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  20. Clinical features and outcomes of atezolizumab-associated encephalitis
    Chunjiang Wang, Wei Sun, Liping Peng +1
    Frontiers in immunologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  21. Systemic immune activation coexists with compartment-specific regulatory enrichment in matched blood, peritumor, and tumor tissue from advanced oral squamous cell carcinoma
    Nayane Alves de Lima Galdino, Flávio Pignataro-Oshiro, João Figueira Scarini +10
    Frontiers in immunologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  22. RTK–RAS pathway alterations in hepatocellular carcinoma and cholangiocarcinoma: a multicohort genomic and single-cell transcriptomic study
    Chongyuan Chen, Rongchun Xing, Yuhong Wen +2
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  23. Research progress in intratumoral microbiota: unlocking the potential of cancer immunotherapy
    Tian Tian, Min Chen
    Frontiers in immunologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  24. Bibliometric analysis of VR interventions in cancer research based on multiple databases: mapping research hotspots and developmental trends
    Ruihan Wang, Yujie Zhang, Lidong Fang +1
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  25. Reshaping the definition of high-risk disease in the immune effector therapy era in multiple myeloma
    Yoshito Nishimura, Gunjan Gaur, Francesca Cottini +1
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref